Outcomes of “one‐day” vs “two‐day” injection protocols using Tc‐99m tilmanocept for sentinel lymph node biopsy in breast cancer

Abstract No prior studies have compared Tc‐99m tilmanocept (TcTM) one‐day and two‐day injection protocols for sentinel lymph node (SLN) biopsy in breast cancer (BC). We retrospectively identified patients with clinically node‐negative BC undergoing SLN biopsy at our institution. Patients received a single, intradermal peritumoral injection of TcTM on day of surgery or day prior to surgery in addition to an intraoperative injection of isosulfan blue dye. Univariable and multivariable Poisson regression count models were constructed to assess the effects of injection timing, radiologist, patient and surgeon characteristics on the number of removed SLNs. A total of 617 patients underwent SLN biopsy with TcTM and blue dye. Sixty‐seven (10.9%) patients were injected with the two‐day protocol. Patients in the one‐day protocol had a mean of 3.0 (standard deviation (SD) 1.9) SLNs removed compared with 2.7 (SD 1.4) SLNs in the two‐day protocol, P‐value = .13. On multivariable analysis, patient age and operating surgeon significantly affected the number of removed SLNs; however, the injection timing and the nuclear radiologist did not influence the number of removed SLNs. The performance of Tc‐99m tilmanocept did not differ significantly between one‐day and two‐day injection protocols. These results are similar to other radiotracers used for SLN biopsy in BC.
Source: The Breast Journal - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research